Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease

https://doi.org/10.1016/S0304-3940(00)00991-5Get rights and content

Abstract

We studied genetic polymorphisms in the promoter region (position -511) and exon 5 (position +3953) of the interleukin (IL)-1β gene in 122 Japanese patients with Parkinson's disease (PD) and 112 controls. We also examined polymorphisms in the IL–1α and the IL–1 receptor antagonist genes. No significant difference was found in these genetic markers between PD patients and controls. However, PD patients with homozygotes for allele 1 at position -511 of the IL–1β gene (IL–1B-511*1), a low producer of IL–1β, were significantly earlier in the disease onset than those with the IL–1B-511*2 homozygotes, a high producer of IL–1β. This suggests that IL–1β might play a role, possibly a protective effect for dopaminergic neurons, in PD. Further population and functional studies are necessary to clarify the role of IL–1β in PD patients.

Section snippets

Acknowledgements

This work was supported by a Grant-In-Aid for Scientific Research from Ministry of Health and Welfare of Japan.

References (17)

There are more references available in the full text version of this article.

Cited by (92)

  • Genetic modifiers of age-at-onset in polyglutamine diseases

    2018, Ageing Research Reviews
    Citation Excerpt :

    Due to their ubiquitous implication in metabolic processes across neurodegenerative diseases, more variants in mtDNA may eventually be found to be relevant for polyQ-diseases. Interleukin (IL)-1β, a major proinflammatory cytokine, has been associated with AD and PD (Grimaldi et al., 2000; Nishimura et al., 2000). A study in a Japanese SCA6 cohort found that a IL-1β polymorphism in the promoter region, at position 511 (IL-1B-511), significantly affected AO of SCA6 (Nishimura et al., 2001): homozygous carriers of allele 1 (IL-1B-511*1) showed earlier disease onset than those with allele 2 (IL-1B-511*2).

  • Neuroinflammation as a therapeutic target in neurodegenerative diseases

    2017, Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies
  • Association of microtubule associated protein tau/Saitohin (MAPT/STH) MAPT-238bp/STH Q7R polymorphisms and Parkinson's disease: A meta-analysis

    2014, Biochemical and Biophysical Research Communications
    Citation Excerpt :

    Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by progressive loss of dopamine neurons in the substantia nigra [1].

  • Glutathione transferases, regulators of cellular metabolism and physiology

    2013, Biochimica et Biophysica Acta - General Subjects
    Citation Excerpt :

    The mechanism by which GSTO1 mediates its effects on these different neurological diseases is currently unclear. However, GSTO1-1 activity has been implicated in the activation of the pro inflammatory cytokine IL1β and since there have been a number of reports indicating an association between IL1β variants and risk of Alzheimer's and Parkinson's disease it is possible that inflammation may play a common role [178–182]. Because it has been difficult to express recombinant GSTO2-2, it has not been as extensively characterized as GSTO1-1.

View all citing articles on Scopus
View full text